OMCL Stock - Omnicell, Inc.
Unlock GoAI Insights for OMCL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.11B | $1.15B | $1.30B | $1.13B | $892.21M |
| Gross Profit | $471.00M | $499.93M | $588.99M | $554.65M | $413.29M |
| Gross Margin | 42.3% | 43.6% | 45.4% | 49.0% | 46.3% |
| Operating Income | $337,000 | $-19,329,000 | $-2,323,000 | $89.51M | $35.53M |
| Net Income | $12.53M | $-20,371,000 | $5.65M | $77.85M | $32.19M |
| Net Margin | 1.1% | -1.8% | 0.4% | 6.9% | 3.6% |
| EPS | $0.27 | $-0.45 | $0.13 | $1.79 | $0.76 |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 14th 2025 | Wells Fargo | Upgrade | Overweight | $35 |
| October 31st 2024 | BofA Securities | Downgrade | Neutral | $57← $44 |
| August 2nd 2024 | Barclays | Upgrade | Equal Weight | $39← $26 |
| January 3rd 2024 | Barclays | Initiation | Underweight | $33 |
| November 3rd 2023 | BTIG Research | Downgrade | Neutral | - |
| November 3rd 2023 | Wells Fargo | Upgrade | Equal Weight | $28← $39 |
| November 3rd 2023 | Piper Sandler | Upgrade | Overweight | $39← $70 |
| October 11th 2023 | KeyBanc Capital Markets | Downgrade | Sector Weight | - |
| September 26th 2023 | Wells Fargo | Reiterated | Underweight | $39← $56 |
| August 2nd 2023 | Piper Sandler | Downgrade | Neutral | $70← $66 |
| July 20th 2023 | Wells Fargo | Downgrade | Underweight | $56← $65 |
| February 27th 2023 | The Benchmark Company | Upgrade | Buy | $68 |
| November 3rd 2022 | The Benchmark Company | Downgrade | Hold | - |
| September 16th 2022 | KeyBanc Capital Markets | Initiation | Overweight | $130 |
| September 9th 2022 | BofA Securities | Initiation | Buy | $120 |
Earnings History & Surprises
OMCLEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $0.47 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.36 | $0.51 | +41.7% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.31 | $0.45 | +45.2% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.16 | $0.26 | +62.5% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $0.57 | $0.60 | +5.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $0.41 | $0.56 | +36.6% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.16 | $0.51 | +218.8% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.08 | $0.03 | +137.5% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.17 | $0.33 | +94.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $0.45 | $0.62 | +37.8% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $0.28 | $0.57 | +103.6% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $0.07 | $0.39 | +457.1% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.09 | $0.33 | +266.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.94 | $1.00 | +6.4% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.85 | $0.84 | -1.2% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $0.71 | $0.83 | +16.9% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | $0.95 | $0.92 | -3.2% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $0.91 | $1.08 | +18.7% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.80 | $0.97 | +21.2% | ✓ BEAT |
Latest News
Benchmark Maintains Buy on Omnicell, Raises Price Target to $50
📈 PositiveBenchmark Maintains Buy on Omnicell, Raises Price Target to $45
📈 PositiveOmnicell shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
📈 PositiveOmnicell Raises FY2025 Adj EPS Guidance from $1.40-$1.65 to $1.63-$1.73 vs $1.55 Est; Raises FY2025 Sales Guidance from $1.130B-$1.160B to $1.177B-$1.187B vs $1.150B Est
📈 PositiveOmnicell Sees Q4 Adj EPS $0.40-$0.50 vs $0.48 Est; Sees Sales $306.000M-$316.000M vs $295.312M Est
📈 PositiveOmnicell Q3 Adj. EPS $0.51 Beats $0.36 Estimate, Sales $310.631M Beat $295.587M Estimate
📈 PositiveEvoke Pharma And EVERSANA Expand GIMOTI® Access Through Omnicell Partnership With Gastro Health And Large GI Practices, Add OneGI Via Brentwood Pharmacy, Nearly Doubling Specialty Pharmacy Network
📈 PositiveOmnicell Names Baird Radford As CFO, Effective August 26, 2025
➖ NeutralOmnicell stock rises on prospects of improved profitability due to U.S.-China trade truce, buyback
📈 PositiveFrequently Asked Questions about OMCL
What is OMCL's current stock price?
What is the analyst price target for OMCL?
What sector is Omnicell, Inc. in?
What is OMCL's market cap?
Does OMCL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OMCL for comparison